This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2004 May;4(5):335-48.

doi: 10.1038/nrc1362.

The TOR pathway: a target for cancer therapy

Mary-Ann Bjornsti¹, Peter J Houghton

Affiliations

PMID: 15122205
DOI: 10.1038/nrc1362

Review

The TOR pathway: a target for cancer therapy

Mary-Ann Bjornsti et al. Nat Rev Cancer. 2004 May.

. 2004 May;4(5):335-48.

doi: 10.1038/nrc1362.

Authors

Mary-Ann Bjornsti¹, Peter J Houghton

Affiliation

¹ Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

PMID: 15122205
DOI: 10.1038/nrc1362

No abstract available

PubMed Disclaimer

Similar articles

Retroviral oncogenes and TOR.
Aoki M, Vogt PK. Aoki M, et al. Curr Top Microbiol Immunol. 2004;279:321-38. doi: 10.1007/978-3-642-18930-2_19. Curr Top Microbiol Immunol. 2004. PMID: 14560966 Review.
Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ, Pollak M, Sonenberg N. Dowling RJ, et al. BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. BioDrugs. 2009. PMID: 19489650 Review.
Prospects for mTOR targeting in adult T cell leukemia.
Altman JK, Platanias LC. Altman JK, et al. Leuk Lymphoma. 2009 Apr;50(4):525-6. doi: 10.1080/10428190902741505. Leuk Lymphoma. 2009. PMID: 19373648 No abstract available.
mTOR inhibition and adult T-cell leukemia.
Hirase C, Maeda Y, Yamaguchi T, Miyatake J, Kanamaru A. Hirase C, et al. Leuk Lymphoma. 2009 Apr;50(4):645-7. doi: 10.1080/10428190802709446. Leuk Lymphoma. 2009. PMID: 19373664 No abstract available.
[Advances on PI3K/Akt/mTOR signalling pathway in malignancies].
Yu BH, Zhou XY. Yu BH, et al. Zhonghua Bing Li Xue Za Zhi. 2005 Oct;34(10):674-6. Zhonghua Bing Li Xue Za Zhi. 2005. PMID: 16536284 Review. Chinese. No abstract available.

See all similar articles

Cited by

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.
Shen C, Oswald D, Phelps D, Cam H, Pelloski CE, Pang Q, Houghton PJ. Shen C, et al. Cancer Res. 2013 Jun 1;73(11):3393-401. doi: 10.1158/0008-5472.CAN-12-4282. Epub 2013 Apr 30. Cancer Res. 2013. PMID: 23633493 Free PMC article.
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.
Adib E, Klonowska K, Giannikou K, Do KT, Pruitt-Thompson S, Bhushan K, Milstein MI, Hedglin J, Kargus KE, Sholl LM, Tsuji J, Hyman DM, Sisk A, Shapiro GI, Vargas HA, Harding JJ, Voss MH, Iyer G, Kwiatkowski DJ. Adib E, et al. Clin Cancer Res. 2021 Jul 15;27(14):3845-3853. doi: 10.1158/1078-0432.CCR-20-4548. Epub 2021 Mar 16. Clin Cancer Res. 2021. PMID: 33727259 Free PMC article. Clinical Trial.
Triterpenes in cancer: significance and their influence.
Gill BS, Kumar S, Navgeet. Gill BS, et al. Mol Biol Rep. 2016 Sep;43(9):881-96. doi: 10.1007/s11033-016-4032-9. Epub 2016 Jun 25. Mol Biol Rep. 2016. PMID: 27344437 Review.
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.
Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Squillace RM, et al. Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18. Int J Oncol. 2012. PMID: 22614157 Free PMC article.
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
Seki Y, Yamamoto N, Tamura Y, Goto Y, Shibata T, Tanioka M, Asahina H, Nokihara H, Yamada Y, Shimamoto T, Noguchi K, Tamura T. Seki Y, et al. Cancer Chemother Pharmacol. 2012 Apr;69(4):1099-105. doi: 10.1007/s00280-011-1788-4. Epub 2011 Dec 6. Cancer Chemother Pharmacol. 2012. PMID: 22143378 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- ClinicalTrials.gov
Molecular Biology Databases
- Saccharomyces Genome Database
Miscellaneous
- NCI CPTAC Assay Portal